

Juan Carlos Sanz^{a,b,*}, Belén Ramos^a, Mayte Pérez-Olmeda^c
y Aurora Fernández-García^{b,c}

^a Laboratorio Regional de Salud Pública de la Comunidad de Madrid,
Dirección General de Salud Pública, Consejería de Sanidad
Comunidad de Madrid, Madrid, España

^b Consorcio de Investigación Biomédica de Epidemiología y Salud
Pública (CIBERESP), España

^c Laboratorio de Referencia e Investigación en Enfermedades Virales
Inmunoprevenibles, Centro Nacional de Microbiología, Instituto de
Salud Carlos III, Madrid, España

* Autor para correspondencia.

Correo electrónico: juan.sanz@salud.madrid.org (J.C. Sanz).

<https://doi.org/10.1016/j.eimc.2021.11.008>

0213-005X/ © 2021 Sociedad Española de Enfermedades Infecciosas y Micro-
biología Clínica. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Subacute thyroiditis after COVID-19 vaccination



Tiroiditis subaguda tras la vacunación con COVID-19

Dear Editor:

We would like to share ideas on the publication “Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine.”¹ Rebollar reported a case and mentioned for possible clinical association between thyroid problem and COVID-19 vaccination.¹ Thyroid problem might be followed vaccination and the pathogenesis is still inconclusive. Regarding subacute thyroiditis, there are sporadic case reports in COVID-19 vaccine recipients.^{2,3} The observed thyroid abnormality might or might not be associated with vaccination. After vaccination, the abnormal thyroid function might occur and it is not related to any immunological abnormality.⁴ Hyperviscosity might occur after vaccination⁴ and it can result in an aberrantly thyroid function.⁵

Authors contribution

SY (50%): (1a) Substantial contributions to study conception and design. (1b) Substantial contributions to acquisition of data. (1c) Substantial contributions to analysis and interpretation of data. (2) Drafting the article or revising it critically for important intellectual content. (3) Final approval of the version of the article to be published.

VW (50%): (1a) Substantial contributions to study conception and design. (1b) Substantial contributions to acquisition of data. (1c) Substantial contributions to analysis and interpretation of data. (2) Drafting the article or revising it critically for important intellectual content. (3) Final approval of the version of the article to be published.

Funding

No funders pertaining to this article.

Conflict of interest

The authors ask for waiving for any charge relating to this correspondence.

Bibliografía

1. Rebollar AF. Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine. *Enferm Infecc Microbiol Clin.* 2021;(November), <http://dx.doi.org/10.1016/j.eimc.2021.10.015> [online ahead of print].
2. Sözen M, Topaloglu Ö, Çetinarslan B, Selek A, Cantürk Z, Gezer E, et al. COVID-19 mRNA vaccine may trigger subacute thyroiditis. *Hum Vaccin Immunother.* 2021;10(December):1–6.
3. Jeeyavudeen MS, Patrick AW, Gibb FW, Dover AR. COVID-19 vaccine-associated subacute thyroiditis: an unusual suspect for de Quervain's thyroiditis. *BMJ Case Rep.* 2021;14, e246425.
4. Mungmunpuntantip R, Viroj Wiwanitkit V. Abnormal thyroid function following COVID-19 vaccination. *Indian J Endocrinol Metab.* 2021;25:169.
5. Joob B, Wiwanitkit V. Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19. *Clin Appl Thromb Hemost.* 2021;27, <http://dx.doi.org/10.1177/10760296211020833>.

Sora Yasri^{a,*}, Viroj Wiwanitkit^b

^a KM Center, Bangkok, Thailand

^b Dr DY Patil University, Pune, India

* Corresponding author.

E-mail address: sorayasri@outlook.co.th (S. Yasri).

<https://doi.org/10.1016/j.eimc.2021.12.010>

0213-005X/ © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Respuesta a "Tiroiditis subaguda tras la vacunación con COVID-19"



Reply to "Subacute thyroiditis after COVID-19 vaccination"

Sr. Editor:

La carta de Yasri y Wiwanitki¹ sobre mi reporte de caso² especula sobre la asociación de vacunación anti COVID-19, hiper-

viscosidad sanguínea y disfunción tiroidea. No existe una relación fisiopatológica descrita entre hiperviscosidad y «función tiroidea aberrante». Las mediciones hormonales tiroideas espurias ocasionadas por la hiperviscosidad sanguínea y la disfunción tiroidea no deben ser confundidas.

La hiperviscosidad por componentes acelulares (proteínas), que pueden ser monoclonales o policlonales, son causa conocida de posible interferencia en los inmunoanálisis usados en tiroides³; entre estas entidades poco comunes se encuentran: macroglobu-